

EyeGate Pharmaceuticals, Inc.

*Providing innovative products that enhance drug efficacy
and patient compliance to improve vision*

Issuer Free Writing Prospectus
Filed Pursuant to Rule 433
Registration No. 333-197725
October 24, 2014

Some of the matters discussed in this presentation contain forward-looking statements that involve significant risks and uncertainties, including statements relating to the prospects for the Company's lead product EGP-437, for the timing and outcome of the Company's clinical trials, the potential approval to market EGP-437, and the Company's capital needs. Actual events could differ materially from those projected in this presentation and the Company cautions investors not to rely on the forward-looking statements contained in, or made in connection with, the presentation.

Among other things, the Company's clinical trials may be delayed or may eventually be unsuccessful. The Company may consume more cash than it currently anticipates and faster than projected. Competitive products may reduce or eliminate the commercial opportunities of the Company's product candidates. If the FDA or foreign regulatory agencies determine that the Company's product candidates do not meet safety or efficacy endpoints in clinical evaluations, they will not receive regulatory approval and the Company will not be able to market them. Operating expense and cash flow projections involve a high degree of uncertainty, including variances in future spending rate due to changes in corporate priorities, the timing and outcomes of clinical trials, regulatory and developments and the impact on expenditures and available capital from licensing and strategic collaboration opportunities. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly alter, delay, scale back or discontinue operations.

Additional risks and uncertainties relating to the Company and its business can be found in the "Risk Factors" section of the Company's Registration Statement on Form S-1, as amended to date. The Company undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or changes in the Company's expectations, except as required by applicable law.

- This presentation highlights basic information about us and the offering. Because it is a summary, it does not contain all of the information that you should consider before investing in our company.
- We have filed a registration statement (including a prospectus) with the United States Securities and Exchange Commission (SEC) for the offering to which this presentation relates. The registration statement has not yet become effective. Before you invest, you should read the prospectus in the registration statement (including the risk factors described therein) and other documents we have filed with the SEC for more complete information about us and the offering. You may get these documents, including the preliminary prospectus dated September 26, 2014, for free by visiting EDGAR on the SEC website at <http://sec.gov>. The preliminary prospectus, dated September 26, 2014, is available on the SEC website at http://www.sec.gov/Archives/edgar/data/1372514/000114420414058162/v390076_s1a.htm
- Alternatively, we or any underwriter participating in the offering will arrange to send you the prospectus if you contact Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone 212-813-1010, email: prospectus@aegiscap.com

Initial Public Offering Summary



Issuer	Eyegate Pharmaceuticals, Inc.
Exchange / Ticker	NASDAQ Capital Market / EYEG
Offering Size	1,923,077 shares (100% primary)
Over-Allotment	15% or 288,462 shares (100% primary)
Price Range	\$12.00 - \$14.00
Use of Proceeds	Complete clinical development of lead program for anterior uveitis indication. Advance additional program to IND filing. Working capital and other general purposes.
Sole Bookrunner	Aegis Capital Corp.

Management Team



▪ **Stephen From, President & CEO**

- With EyeGate since October 2005
- Former CFO, Centelion SAS (Aventis subsidiary)
- Healthcare investment Banker
- Qualified Chartered Accountant (PwC)

▪ **Michael Manzo, VP Engineering**

- With EyeGate since October 2006
- Over 30 years of experience in product development and manufacturing in the medical device industry
- Former President and COO, Jenline Industries (now part of Helix Medical)
- Senior Marketing Engineer, ONUX Medical

▪ **Paul Perkins, Sr. Director, Finance and HR**

- With EyeGate since October 2006
- Former CFO, Masonic Health System
- Managed Finances and Human Resources at various other corporations

▪ **Michael Patane Ph.D., CSO (Consultant)**

- Exec. Director, Global Discovery Chemistry, Novartis, responsible for infectious diseases and ophthalmology
- Director, Medicinal Discovery, Millennium Pharma

▪ **Michael Raizman M.D., CMO (Consultant)**

- Specialist in Laser Vision Correction and Treatment of the Cornea, Ophthalmic Consultants of Boston
- Associate Professor of Ophthalmology, Tufts University

▪ **Lisa Brandano, Director, Clinical Operations**

- Former Assistant Managing Director of the Boston office and Director, Clinical Trial Operations, CATO Research
- Beth Israel Deaconess Medical Center, Boston

Selected Board Members

- **Paul Chaney (Chairman)**
 - President and CEO of PanOptica, Inc.
 - 25 years experience in pharmaceutical industry including several VP positions at Pharmacia
- **Morton Goldberg M.D.***
 - Joseph E. Green Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University School of Medicine
 - Former Director and William Holland Wilmer Professor of Ophthalmology, Wilmer Eye Institute
- **Praveen Tyle PhD.**
 - President and CEO of Osmotica Pharma.
 - SVP and Global Head Business Development & Licensing for Novartis Consumer Health OTC
 - Former VP of R&D and Chief Scientific Officer for Bausch & Lomb

Selected Medical Advisors

- **Victor Perez M.D.**
 - Director of the Ocular Surface Center and the Walter G. Ross Distinguished Chair in Ophthalmic Research Programs at the Bascom Palmer Eye Institute
 - Professor of Ophthalmology, Microbiology and Immunology, University of Miami Miller School of Medicine
- **John Sheppard M.D.**
 - President, Virginia Eye Consultants: Research, Education & Clinical Excellence
 - Professor of Ophthalmology, Microbiology & Molecular Biology, Ophthalmology Residency Research Director, Clinical Director, Thomas R. Lee Center for Ocular Pharmacology, Eastern Virginia Medical School
- **Stephen Foster M.D.**
 - Founder and Director of the Massachusetts Eye Research and Surgery Institute (MERSI)
 - Author of over 500 published books and papers and has won numerous awards including The International Ocular Inflammation Society Award and The American Academy of Ophthalmology Senior Honor Award

- **Late-stage specialty pharmaceutical and drug delivery company targeting highly prevalent ocular indications**
 - Lead investors include Ventech, IPSA, Natixis

- **Lead product candidate, EGP-437 for anterior uveitis, matched response rate for standard of care in non-inferiority trial**
 - 505(b)(2) NDA filing scheduled for end of 2016 and targeting 2017 commercial launch
 - EGP-437 being evaluated for multiple other indications

- **EyeGate II® Delivery System: Proprietary, non-invasive delivery platform; >1,700 treatments performed to-date**
 - System is approved through a 510(k) filing at time of drug NDA submission
 - Easy to use; can be done by ophthalmologist or optometrist in <5 minutes
 - Delivers small and large molecules to anterior or posterior of eye
 - Significant patient and clinician advantages over drops or ocular injections
 - Safer, lower-risk alternative to intravitreal injection

- **Late-stage lead asset with clear path to commercialization**
 - EGP-437 completed first Phase 3 trial in Anterior Uveitis, and one pivotal trial left to complete, NDA submission expected 2016; Targeting 2017 commercial launch

- **Robust clinical and development program to maximize market opportunity**
 - EGP-437 clinical trials underway for additional indications, including Diabetic Macular Edema
 - Additional compounds ready for development
 - Longer-term opportunity in non-invasive macular degeneration treatment or long-acting glaucoma treatment

- **EyeGate® II Delivery System – a potential paradigm-shift in ophthalmic drug administration**
 - Treatment can be performed by range of eye care professionals (injectables must be administered by an experienced ophthalmologist)
 - Long-lasting, professionally delivered treatment eliminates compliance risk of patient-administered drops


- **Robust US and international patent portfolio**
 - Protection from 2018 through 2029*

*Granted patent protection until 2024, applications if granted extend this to 2029

Unique Ophthalmic Delivery Platform




Anterior Segment of the Eye




- Primary mode of delivery is eye drops
- Problem: protective layer and biological functions limit penetration of drug into tissues
- Frequent instillations required: up to 16 per day
- Extremely heavy burden on patient resulting in non-compliance
- Can result in sight-threatening complications

Posterior Segment of the Eye




- Primary mode of delivery is via intravitreal injection
- Safety concerns with potential for collateral damage
- Injections as frequent as monthly
- Must be completed by experienced ophthalmologist
- Excessive travel and companion required results in non-compliance
- Can result in sight-threatening complications

EyeGate has the only Non-Invasive Solution



Iontophoresis

- Small electrical current (constant); Current has same charge as active substance (drug)
- Electrode creates repulsive electromotive forces (electrorepulsion)
- Drug migrates toward return electrode
- Drug delivered in high local concentration with minimized systemic absorption
- Drug mobility is a function of molecular weight, solubility, and charge
- Single system can deliver multiple drugs to treat multiple indications
- Iontophoretic dose (mA-min) = Current (mA) x Application time (minutes)
- Software-regulated current and duration ensures proper dosing of compatible compounds





Self-administered Eye Drops



**EyeGate® II
Delivery system**



Intravitreal Injections

No more self-administered drops

No more injections



- **New revenue stream for physicians (CPT Code)**
- Can be performed by variety of ophthalmic / optometry staff
- Quick; Average treatment time <5 minutes, with no waiting
- Able to treat any patient at any time
- Less travel for patient and companion not required to accompany patient
- Improve patient compliance, main cause of treatment failure
- "Fear factor" of ocular injection is eliminated

Program	Indication	Current Status	Use of Proceeds Milestones
EGP-437	Anterior Uveitis	<ul style="list-style-type: none"> Phase 1-2 dose ranging trial completed First non-inferiority trial completed 	<ul style="list-style-type: none"> Initiate and complete Phase 3 pivotal trial
	Dry Eye	<ul style="list-style-type: none"> Two trials completed (Phase 2 & Phase 3) (Stress Environment - placebo controlled) 	<ul style="list-style-type: none"> No further trials are anticipated with use of proceeds
	Cataract Surgery	<ul style="list-style-type: none"> Phase 2 proof of concept trial completed (prophylactic - placebo controlled) 	
	General		<ul style="list-style-type: none"> Assess and initiate Phase 2 proof of concept trial(s) Initiate corneal endothelial cell count safety trial Complete drug manufacturing validation batches
Research		<ul style="list-style-type: none"> Demonstrated <i>in vivo</i> (preclinical) delivery of multiple therapeutic classes 	<ul style="list-style-type: none"> Select Candidate Complete formulation work Initiate and complete preclinical studies Initiate and complete IND enabling studies Submit IND

EGP-437
Anti-Inflammatory

Uveitis Overview

- Inflammation of the uveal tract may be idiopathic, associated with systemic diseases or result from a variety of infectious agents
- An annual estimated 17.6% of active uveitis patients experience transient or permanent loss of vision. Uveitis is responsible for more than 2.8% of blindness in the U.S.
- Non-infectious anterior uveitis is a debilitating form of inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body and is the most common form of uveitis
- Incidence in the U.S. ranges from approximately 26.6 – 102 per 100,000 adults annually
- Chronic or recurrent, anterior uveitis and non-compliance of treatment may lead to complications such as posterior subcapsular cataract, glaucoma and macular edema



Non-compliance leads to sight-threatening complications

EGP-437: A Highly Differentiated Product

Dramatically Reduces Patient Burden from 154 to 3 Treatments



Standard of care to treat anterior uveitis is patient administered corticosteroid eye drops

- Topical corticosteroids suffer from a number of drawbacks including low ocular bioavailability, rapid clearance and steroid-related side effects, including elevated intraocular pressure, or IOP
- At minimum, patients are required to give themselves 154 treatments of the standard of care
- Given heavy burden, patient non-compliance is prevalent and is the main cause of treatment failure
- Alternative is more aggressive steroid therapy, such as ocular and intravenous injections, which is often associated with steroid-related adverse effects such as elevated IOP and cataract formation



vs.




2 to 3 treatments

154 treatments

Anterior Uveitis Episode 1994




OD
20/20




OS
20/80
"low grade chronic inflammation"



Same Patient 10 Years Later (2004): Poor Anti-Inflammatory Therapeutics



OD
20/400
Legally Blind



OS
No Light Perception
"Blind"

Severity of Uveitis: SUN Working Group

- Debilitating form of intraocular inflammation of the anterior portion of the uvea
- Confirmation and severity of disease is determined by the number of white blood cells in the anterior chamber of the eye (Slit-lamp is used)
- The Standardization of Uveitis Nomenclature (SUN) working group of 2004 agreed that inactive disease (cell count of zero) is the goal of therapy
- The SUN group created a grading scheme for determining degree of inflammation
- Subjects required minimum 11 cells to be randomized to our study

Grade	Cells
0	< 1
0.5	1 to 5
1.0	6 to 15
2.0	16 to 25
3.0	26 to 50
4.0	> 50

Non-Infectious Anterior Segment Uveitis (>11 cells) non-inferiority Trial


- **Primary objective:** evaluate whether EGP-437 using the EyeGate® II Drug Delivery System (EGDS) is non-inferior to topical ophthalmic prednisolone acetate ophthalmic suspension (1%) (positive control) in patients with non-infectious anterior segment uveitis
- **Primary End Point (PEP):** Total cell clearing at Day 14
 - Patients exhibit a large number of white blood cells in the anterior chamber of the eye
 - In order to count these cells in the anterior chamber, the physician uses a slit lamp, focusing a thin sheet of light into the eye. The treatment objective is to eliminate the inflammation of the uvea which can be confirmed by an anterior chamber cell count of zero

Initial Phase 3 Non-Inferiority Anterior Uveitis Trial

Trial Design and High-Level Results



Trial Design




- 35 sites enrolled subjects: all in the U.S.
- 193 Subjects were randomized 1:1 to 2 arms
 - 2 EGP-437 iontophoresis treatments + placebo eye drops (N = 96)
 - 2 placebo iontophoresis treatments + Pred Acet eye drops (N = 97)

High-Level Results

- Successfully demonstrated same response rate when comparing EGP-437 to standard of care (prednisolone acetate 1%) in Phase 3 trial of 193 patients with anterior uveitis
- Lower incidence of increased intraocular pressure (IOP) with EGP-437 treatment

Percent of subjects with cell count of 0 at each visit*




*Per Protocol population
** PEP = Primary Endpoint

Both treatments are associated with similar Treatment Emergent Adverse Events (TEAEs) profiles.



- No adverse events occurred in a frequency >10%

IOP Increases: Incidents and Subjects.



- Each subject had four IOP measurements (Day 7, 14, 28, and 56) compared to baseline (Day 0)
- Significantly less subjects with incidents in the EGP-437 arm
- 2.4X the number of incidents in the control arm

Subjects and Incidences of IOP increases from baseline

- Just outside non-inferiority margin

Primary Endpoint: AC Cell Count = 0 at Day 14	ITT* (N = 193)	
	EGP-437	PA 1%
Subjects with Day 14 AC Cell Count = 0	32	32
Total Number of Subjects	96	97
Proportion	33.3%	33.0%
Difference (%) (95% CI)	0.34 (-12.94%, 13.63%)	

- Proportion of subjects randomized with fewer than 25 cells (least severe population) was significantly higher in the control arm at baseline. Important as response rate similar for both arms in this population (43.2% vs 41.4% for EGP-437 vs PA 1% respectively).

	Enrolled	EGP-437		PA 1%		PEP	
		No.	%	No.	%	No.	%
11 to 25 cells	102	44	43.1%	58	56.9%	43	42.2%
> 25 cells	91	52	57.1%	39	42.9%	21	23.1%
	193	96	49.7%	97	50.3%	64	33.2%


* ITT = intent to treat or full population,

Primary Endpoint

Results by Severity (ITT Population)




- EGP-437 has demonstrated equivalent response rates for SUN grades 1.0, 2.0 and 3.0 and has demonstrated much better results (29% better) for the more severe 4.0 grade.
- Combining SUN grades 3.0 and 4.0 results in 25.0% and 20.5% response rates for EGP-437 and PA1% respectively.



Modified design provides stronger powering for non-inferiority PEP* and ability to show SUPERIORITY for more severe** population whilst maintaining similar trial size

- Modification: Three (3) treatments of EGP-437 prior to Day 14 primary endpoint (PEP)
- N: 250 subjects (90% powering for non-inferiority PEP with whole population)
- Randomization will be stratified by the baseline severity of the condition, according to the SUN scale, to ensure a more even distribution between the two treatment groups
- Subjects randomized to SUN groups 1.0 and 2.0 will be limited to approximately 120 subjects
- Primary endpoint is non-inferiority for whole population
- Secondary endpoint for superiority of the more severe group (> 26 cells)
- Provides ability to put both claims on the label



* PEP = Primary Endpoint

** SUN Grade 3.0 (26 cells) or greater

NDA Filing: Anterior Uveitis

- Year-end 2016

Filing NDA for anterior uveitis (<\$12 million¹)

- Phase 3 pivotal anterior uveitis study (~\$8 million)
 - Design modified: 3 treatments, N = 250 and seek superiority for severe patients
- Endothelial cell count safety study (~\$2 million)
 - 6-month endpoint on 100 eyes
- CMC validation: drug and device (~\$1.5 million)
- NDA Filing (~\$250k)

1. does not include working capital

Confirmatory Phase 3 Trial

- Initiation: Q4 2014
- First Patient In (FPI): Q1 2015
- Last Patient In (LPI): Q1 2016
- Top-Line Date: Mid-year 2016

Endothelial Safety Trial

- Initiation: Q2 2015
- Top-Line Date: Q2 2016

POC Phase 2 Trials for Additional Indications: allocated \$1.3 million from proceeds

▪ First Trial

- Initiation: Q2 2015
- Top-line data: Q3 2015


▪ Second Trial

- Initiation: Q3 2015
- Top-line data: Q4 2015

- **Clearly-defined and sufficiently concentrated universe of clinicians that treat anterior uveitis in the U.S. which can be addressed by small, focused specialty sales team**
- **Plan to build key capabilities to support specialty sales team**
 - Marketing, market access, sales management and medical affairs
- **Opportunity to grow overall market by enabling new point-of-care options**
 - Injectable therapies limit administration to experienced ophthalmologist only
 - EGP-437 via EyeGate® II Delivery System can be administered by optometrist, nurse and other staff
- **Incremental opportunity through international commercialization**
 - Intend to enter into strategic collaboration for commercialization outside the U.S.

Single-Use Kit

- Includes device and drug
- Combining drug vial and device disposables together:
 - Ensures use of approved drug with applicator
 - Provides simplification of inventory and invoicing
- Shelf-life established at 24 months (drug and applicator)



Reimbursement: In-office treatment and physician office billing involves multiple code sets.

- **CPT Code:** In addition to office reimbursement, clinic receives reimbursement for performing treatment
- **J-code:** The kit (drug + disposables) will be billed under a J-code Payment that would be based on ASP (price we establish) + x% for the kit. EyeGate sells kit to clinic

Additional Programs And Corporate

▪ **Macular Degeneration (AMD)**

- Two primary drugs approved, both proteins and injected locally, treat prevalent retinal diseases (i.e. AMD): multibillion dollar market
- EyeGate platform provides the **ONLY** non-invasive way to deliver proteins into the eye
- Demonstrated ability to deliver various classes of drugs suitable for AMD
 - E.g. small molecules, proteins

▪ **Delivery of molecules not suitable for topical formulation (Medical Need)**

- Various rare (orphan) diseases exist whereby our platform would be ideal for treatment i.e. anti-infectives
- Other reformulated generics suitable for ocular iontophoresis
 - Use EGP-437 as a template for clinical development

▪ **Nanoparticles**

- Demonstrated ability to penetrate to sclera non-invasively
- Provides vehicle for long-acting products: small molecules
 - E.g. glaucoma product - prostaglandin



New IP generated for device and therapeutic – extending market exclusivity period

EyeGate® II




- Foam reservoir for drug
- Circular design
- Therapeutic supplied in separate vial
- Transfer system required to fill applicator

Next Generation



- **Pre-filled with therapeutic**
- Eliminates need for transfer system
- Smaller package design
- Oval ocular interface facilitates placement



Current EyeGate® II profile

Re-Usable Generator

EyeGate® II



- Current generator in clinical use


Touchscreen Version



- Easy to program
- Allows for custom menus
- Ability to upgrade interface via firmware

Disposable Generator

Generator integrated with return electrode generator



- Dose and current pre-programmed during manufacturing
- No serviceable parts
- Option to customize program with interface and mobile app


Timelines allow for next generation re-usable and/or disposable generator to be available for commercial launch



Eleven families (68 patents granted)

- **Eight belong to the “ever growing” delivery system patent portfolio**
 - 13 U.S. and 55 foreign patents granted
 - 2 U.S. and 20 foreign pending applications

- **Three relate to drug compositions and treatments utilizing delivery system:**
 - 4 U.S. and 8 foreign applications



Protection from 2018 through 2029*

* Granted patent protection until 2024, applications # granted extend this to 2029

EGP-437

- **Phase 3 Trial**
 - FPI: Q1 2015
 - Phase 3 trial top-line data: mid 2016 – non-inferiority with potential for superiority with more severe population on the label
- **Endothelial Cell Count Safety Trial**
 - Commences: Q2 2015
 - Top-line data: Q2 2016
- **First POC Phase 2 Trial**
 - Commences: Q2 2015
 - Top-line data: Q3 2015 – opportunity: validate posterior delivery in clinic
- **Second POC Phase 2 Trial**
 - Commences: Q3 2015
 - Top-line data: Q4 2015 – opportunity: expansion of label for large market

Other

- **Second Project**
 - 2015: Formulation work and preclinical studies
 - 2016: Pre-IND enabling studies and IND filed
- **Device**
 - Next generation system

Ophthalmology Class of IPO's Last Twelve Months



OPHTHALMOLOGY CLASS: LTM				Share Price			Valuation Millions (Oct 22)
Listing Date	Company	Ticker	Stage of Lead Product	Offer	Current (Oct 22 close)	Current % Change	
07/30/2014	Avalanche Biotechnologies, Inc.	AAVL	Phase 1/2	\$17.00	\$32.64	92.0%	\$697
07/24/2014	Ocular Therapeutix, Inc.	OCUL	Commercial	\$13.00	\$13.62	4.8%	\$290
03/26/2014	Applied Genetic Technologies	AGTC	Pre-Clinical	\$12.00	\$17.93	49.4%	\$288
02/05/2014	Eleven Biotherapeutics, Inc.	EBIO	Phase 2	\$10.00	\$10.56	5.6%	\$163
10/24/2013	Aerie Pharmaceuticals, Inc.	AERI	Phase 2	\$10.00	\$22.28	122.8%	\$532
				AVERAGE	\$19.41	56.5%	\$394
				ALL**		9.9%	\$274
EyeGate Pharma*				EYEG	Phase 3	\$13.00	\$90
					High	122.8%	\$697
					Low	4.8%	\$163

*Share price and valuation at mid-point of price range

** 91 companies: PRTO, ATRA, FWP, DERI, CALA, VTAE, FOMX, PRQR, TKA, APVD, RWLK, OTIG, TTDG, EARS, LOXD, MRNS, ORPN, NCUR, AAVL, PFIX, INNL, OCUL, JENT, IIOZ, CDNA, SAGE, ROKA, GBII, NERV, AMPH, KITE, ZPQN, PARN, AROX, SGNL, ZBPH, ROUS, AGRX, KTMD, ALDR, SOYX, ALOX, EVAR, QTNT, VTL, TRIV, PAHO, CERU, ADMS, OORI, AGTC, RTGN, VBAR, IDWD, AKBA, DRRX, GLVD, AKAO, RERH, AZXP, LMNS, SMLR, INGN, AMDA, CNCE, BDRX, FLJN, NRX, ARGS, EGLT, EBIO, RVNO, QURE, BIOC, ASRX, GNCA, TRVN, CARA, RARE, DRNA, CLDN, GLYC, TLOG, KIN, XNOR, OYFO, RLYR, TNDM, KPTI, VOYT, AERI

Capitalization	Shares Outstanding	% Outstanding
Common Stock*	5,135,944	76.8%
Stock Options	1,543,559	23.1%
Warrants	7,246	0.1%
Fully-Diluted Shares Outstanding	6,686,749	100.0%

*Common Stock number includes Convertible Notes, Warrants and Preferred Stock that convert upon closing of the IPO

- **Late-stage lead asset with clear path to commercialization**
 - EGP-437 completed first Phase 3 trial in Anterior Uveitis, and one pivotal trial left to complete, NDA submission expected 2016; Targeting 2017 commercial launch

- **Robust clinical and development program to maximize market opportunity**
 - EGP-437 clinical trials underway for additional indications, including Diabetic Macular Edema
 - Additional compounds ready for development
 - Longer-term opportunity in non-invasive macular degeneration treatment or long-acting glaucoma treatment

- **EyeGate® II Delivery System – a potential paradigm-shift in ophthalmic drug administration**
 - Treatment can be performed by range of eye care professionals (injectables must be administered by an experienced ophthalmologist)
 - Long-lasting, professionally delivered treatment eliminates compliance risk of patient-administered drops

- **Robust US and international patent portfolio**
 - Protection from 2018 through 2029*

*Granted patent protection until 2024, applications if granted extend this to 2029